Specialty Pharmacy

A record 4.3 billion prescriptions were filled in the United States last year.

Treatment found to lower blood sugar levels in obese mice.

Treatment dramatically reduces viral load in blood.

Low temperature plasmas found to induce high levels of DNA damage.

FDA warns of potential issues from diabetes drugs Onglyza, Kombiglyze, and Nesina.

When reporting diet and exercise, patients may feel pressured to say what they think clinicians want to hear.

Inhibiting a previously undruggable protein holds promise for treatment of numerous types of cancer.

High cost of new drugs make treating even the sickest inmates impractical.

Longer telomeres gives cancer cells a survival advantage.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses innovative new therapies for the treatment of cancer.

CCZ impairs the ability of the virus to enter human liver cells.

Ibrutinib found to control Waldenstrom's Macroglobulinemia in 95% of patients.

Analysis of cancer-causing mutations in the BRCA1 or BRCA2 genes may lead to more effective treatments.

Lack of adherence remains a major source of health care costs among HIV patients.

Study finds that UV tanning meets the same criteria as smoking as a cause of cancer.

New FDA-approved drug used to treat patients with chronic iron overload.

Staying abreast of changes to the 340B Drug Pricing Program is critical for maintaining program compliance.

Accelerated aging of DNA can lead to diseases such as cancer and osteoporosis.

Increased neuron activity helps to protect nerve fibers.

New software platform will complement existing pharmacy software and optimize patient management.

The FDA refused to approve Novo Nordisk's ultra-long-acting insulin treatments 2 years ago.

Vast majority of children with HIV experience recovery of immune system following therapy.

Researchers suggest financial incentives to reward patient-centered care.

Companies to jointly market software to health care providers.

The FDA has granted orphan drug designation to Prolong Pharmaceuticals' sickle cell disease treatment.

Enzyme blocker reduces growth of intestinal tumors.

Prevalence of tanning linked to sharp increase in melanoma risk.

The FDA has granted 2 breakthrough therapy designations to grazoprevir/elbasvir.